35 Early pharmacodynamic changes measured by RNA sequencing in peripheral blood from patients in a phase 1 study with mitazalimab, a potent CD40 agonistic IgG1 monoclonal antibody

Abstract

BackgroundMitazalimab is a human FcgR crosslinking-dependent human IgG1 CD40 agonistic antibody developed for cancer immunotherapy.1–3 Mitazalimab has demonstrated a manageable safety profile when administered once every 2 weeks both with...